Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/IQGAP2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/IQGAP2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/IQGAP2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/IQGAP2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/IQGAP2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/IQGAP2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/IQGAP2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:005125829 | Thyroid | ATC | protein polymerization | 159/6293 | 297/18723 | 9.33e-13 | 3.96e-11 | 159 |
GO:0110053210 | Thyroid | ATC | regulation of actin filament organization | 150/6293 | 278/18723 | 1.82e-12 | 7.58e-11 | 150 |
GO:0051495111 | Thyroid | ATC | positive regulation of cytoskeleton organization | 125/6293 | 226/18723 | 1.39e-11 | 5.08e-10 | 125 |
GO:190290529 | Thyroid | ATC | positive regulation of supramolecular fiber organization | 117/6293 | 209/18723 | 2.19e-11 | 7.80e-10 | 117 |
GO:003253526 | Thyroid | ATC | regulation of cellular component size | 191/6293 | 383/18723 | 2.51e-11 | 8.69e-10 | 191 |
GO:003227129 | Thyroid | ATC | regulation of protein polymerization | 127/6293 | 233/18723 | 3.64e-11 | 1.20e-09 | 127 |
GO:0008154111 | Thyroid | ATC | actin polymerization or depolymerization | 119/6293 | 218/18723 | 1.32e-10 | 4.08e-09 | 119 |
GO:003133428 | Thyroid | ATC | positive regulation of protein-containing complex assembly | 127/6293 | 237/18723 | 1.64e-10 | 4.93e-09 | 127 |
GO:0008064111 | Thyroid | ATC | regulation of actin polymerization or depolymerization | 101/6293 | 188/18723 | 9.88e-09 | 2.05e-07 | 101 |
GO:0030832111 | Thyroid | ATC | regulation of actin filament length | 101/6293 | 189/18723 | 1.43e-08 | 2.92e-07 | 101 |
GO:0030041111 | Thyroid | ATC | actin filament polymerization | 101/6293 | 191/18723 | 2.91e-08 | 5.50e-07 | 101 |
GO:0032273113 | Thyroid | ATC | positive regulation of protein polymerization | 77/6293 | 138/18723 | 6.67e-08 | 1.17e-06 | 77 |
GO:0030833110 | Thyroid | ATC | regulation of actin filament polymerization | 91/6293 | 172/18723 | 1.34e-07 | 2.20e-06 | 91 |
GO:0031532111 | Thyroid | ATC | actin cytoskeleton reorganization | 62/6293 | 107/18723 | 2.01e-07 | 3.17e-06 | 62 |
GO:004308719 | Thyroid | ATC | regulation of GTPase activity | 153/6293 | 348/18723 | 3.24e-05 | 2.68e-04 | 153 |
GO:0030838110 | Thyroid | ATC | positive regulation of actin filament polymerization | 52/6293 | 99/18723 | 7.88e-05 | 5.94e-04 | 52 |
GO:003431418 | Thyroid | ATC | Arp2/3 complex-mediated actin nucleation | 24/6293 | 39/18723 | 3.25e-04 | 2.03e-03 | 24 |
GO:200024914 | Thyroid | ATC | regulation of actin cytoskeleton reorganization | 23/6293 | 39/18723 | 1.01e-03 | 5.34e-03 | 23 |
GO:004501014 | Thyroid | ATC | actin nucleation | 28/6293 | 52/18723 | 2.08e-03 | 9.82e-03 | 28 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0481017 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa04810 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa048101 | Colorectum | AD | Regulation of actin cytoskeleton | 75/2092 | 229/8465 | 3.36e-03 | 1.76e-02 | 1.12e-02 | 75 |
hsa048102 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
hsa048103 | Colorectum | SER | Regulation of actin cytoskeleton | 60/1580 | 229/8465 | 2.74e-03 | 2.02e-02 | 1.47e-02 | 60 |
hsa048104 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
hsa048105 | Colorectum | MSS | Regulation of actin cytoskeleton | 68/1875 | 229/8465 | 4.27e-03 | 1.86e-02 | 1.14e-02 | 68 |
hsa048106 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
hsa048107 | Colorectum | FAP | Regulation of actin cytoskeleton | 65/1404 | 229/8465 | 4.07e-06 | 5.91e-05 | 3.59e-05 | 65 |
hsa048108 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
hsa048109 | Colorectum | CRC | Regulation of actin cytoskeleton | 52/1091 | 229/8465 | 2.34e-05 | 5.57e-04 | 3.78e-04 | 52 |
hsa0481018 | Endometrium | AEH | Regulation of actin cytoskeleton | 50/1197 | 229/8465 | 9.08e-04 | 5.78e-03 | 4.23e-03 | 50 |
hsa0481019 | Endometrium | AEH | Regulation of actin cytoskeleton | 50/1197 | 229/8465 | 9.08e-04 | 5.78e-03 | 4.23e-03 | 50 |
hsa0481024 | Endometrium | EEC | Regulation of actin cytoskeleton | 49/1237 | 229/8465 | 3.20e-03 | 1.78e-02 | 1.33e-02 | 49 |
hsa0481034 | Endometrium | EEC | Regulation of actin cytoskeleton | 49/1237 | 229/8465 | 3.20e-03 | 1.78e-02 | 1.33e-02 | 49 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IQGAP2 | SNV | Missense_Mutation | | c.3481N>T | p.Leu1161Phe | p.L1161F | Q13576 | protein_coding | deleterious(0) | possibly_damaging(0.757) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
IQGAP2 | SNV | Missense_Mutation | novel | c.2327N>T | p.Ser776Phe | p.S776F | Q13576 | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IQGAP2 | SNV | Missense_Mutation | | c.1039N>A | p.Glu347Lys | p.E347K | Q13576 | protein_coding | deleterious(0.05) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IQGAP2 | SNV | Missense_Mutation | novel | c.1718N>T | p.Pro573Leu | p.P573L | Q13576 | protein_coding | tolerated(0.14) | benign(0.125) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IQGAP2 | SNV | Missense_Mutation | rs768262402 | c.3248N>T | p.Ser1083Leu | p.S1083L | Q13576 | protein_coding | deleterious(0.05) | benign(0.34) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IQGAP2 | SNV | Missense_Mutation | | c.1474N>G | p.Gln492Glu | p.Q492E | Q13576 | protein_coding | tolerated(0.68) | benign(0.007) | TCGA-B6-A0WZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
IQGAP2 | SNV | Missense_Mutation | | c.50N>A | p.Ile17Asn | p.I17N | Q13576 | protein_coding | deleterious(0) | possibly_damaging(0.573) | TCGA-E9-A1NA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
IQGAP2 | SNV | Missense_Mutation | novel | c.1166C>T | p.Ser389Phe | p.S389F | Q13576 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
IQGAP2 | SNV | Missense_Mutation | rs528370381 | c.1442C>T | p.Ala481Val | p.A481V | Q13576 | protein_coding | tolerated(0.06) | benign(0.133) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
IQGAP2 | SNV | Missense_Mutation | novel | c.3319C>T | p.Arg1107Trp | p.R1107W | Q13576 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |